GlassScriptPhysician profile
Ishrat A Osman
NPI 1992711808
$1,458.49
in general payments reported to CMS, 2019-2025
20 companies · $223 in 2025
The $223 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.21 · 2020: $163 · 2021: $270 · 2022: $198 · 2023: $237 · 2024: $276 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $736.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $300.40 | 2020-2025 | Bexsero, Pediarix, Shingrix |
| Pfizer INC. | $244.48 | 2022-2025 | |
| Mylan Specialty L.P. | $205.41 | 2020-2022 | |
| Sanofi Pasteur INC. | $150.89 | 2021-2025 | |
| Cranial Technologies, INC | $97.66 | 2019-2025 | Doc Band |
| Janssen Pharmaceuticals, INC | $51.90 | 2019-2021 | |
| Amgen INC. | $51.77 | 2024 | Krystexxa, Repatha |
| Lundbeck LLC | $50.95 | 2021-2023 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $46.93 | 2019-2024 | Rexulti |
| Phadia US INC. | $32.56 | 2019-2021 | |
| Redhill Biopharma INC. | $27.71 | 2020 | |
| Genzyme Corporation | $27.69 | 2025 | |
| Indivior INC. | $25.42 | 2022 | |
| Exact Sciences Corporation | $24.97 | 2023 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $23.81 | 2024 | Aptima |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $23.50 | 2024 | Flucelvax |
| Supernus Pharmaceuticals, INC. | $23.40 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.51 | 2025 | Rexulti |
| Genentech USA, INC. | $15.81 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.72 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ishrat Osman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.